• RCN2 Drives ESCC Metastasis and Cisplatin Resistance via PI3

  2026-08-05

  This study uncovers how RCN2 promotes metastasis and cisplatin resistance in esophageal squamous cell carcinoma (ESCC) by facilitating UBR5-mediated degradation of PPP2CA, resulting in sustained activation of the PI3K-AKT pathway. These mechanistic insights suggest RCN2 as a promising therapeutic target and inform the development of more effective strategies for tackling aggressive, treatment-resistant ESCC.

• Redefining Cell Viability Measurement: Ferroptosis, Zinc, an

  2026-08-04

  Explore how breakthroughs in regulated cell death research—specifically the context-dependent modulation of ferroptosis by ciprofloxacin—demand next-generation cell viability assays. This article bridges mechanistic insight with actionable strategy, showing how APExBIO’s Luminescent ATP Cell Viability Assay Kit I empowers translational researchers to accurately track subtle viability changes and cytotoxic responses, enabling discovery at the frontiers of oncology and drug development.

• Lyso-Tracker Red: Precision Lysosome Labeling in Live Cells

  2026-08-04

  Lyso-Tracker Red enables high-specificity, live-cell lysosomal tracking for advanced studies of cell death and organelle dynamics. Its robust fluorescence and compatibility with modern imaging workflows make it the gold standard for analyzing lysosome integrity, especially in cancer research.

• UK-5099: Transforming Mitochondrial Metabolism Research Prot

  2026-08-03

  UK-5099 (PF-1005023) is redefining mitochondrial metabolism research by enabling robust, reproducible immunometabolic assays. Discover how optimized protocols using UK-5099 unlock precise mitochondrial pyruvate carrier inhibition and advance whole-blood stimulation models.

• New CHAP Model Improves Bleeding Risk Prediction in VTE Care

  2026-08-03

  This study presents the CHAP model, a simplified risk tool that predicts major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism (VTE). Compared to modified existing tools, CHAP provides similar accuracy with improved usability, supporting more tailored clinical decision-making.

• AT13387 Hsp90 Inhibitor: Applied Workflows & Troubleshooting

  2026-08-02

  AT13387 delivers potent, selective Hsp90 inhibition—unlocking advanced cancer biology research with superior oral bioavailability and a unique chemical scaffold. This guide walks through experimental protocols, troubleshooting, and the latest insights linking apoptosis mechanisms to cutting-edge cancer workflows.

• Linezolid Oxazolidinone Antimicrobial: Protocols & Research

  2026-08-01

  Linezolid empowers researchers to dissect Gram-positive resistance at the bench, offering proven workflows for MRSA, VRE, and pneumococcal research. This guide delivers actionable protocols, real-world troubleshooting, and bridges the latest medicinal chemistry advances to practical assay design.

• Dimethyloxalylglycine (DMOG): Protocols and Technical Guidan

  2026-07-31

  Dimethyloxalylglycine (DMOG) is designed for controlled stabilization of hypoxia-inducible factor (HIF) in both in vitro and in vivo research. It enables reproducible modeling of hypoxia signaling and inflammation pathways but is not intended for diagnostic or clinical applications.

• GPR35-KLF5 Circuitry in Epithelial Repair: Insights from DSS

  2026-07-31

  This article analyzes recent research uncovering how GPR35 acts as a metabolic sensor for tryptophan metabolites, orchestrating intestinal epithelial repair through KLF5 signaling. The findings clarify the molecular basis for damage detection and regeneration in colitis, providing a mechanistic foundation for future ulcerative colitis therapies and preclinical modeling.

• Unlocking High-Yield RNA Synthesis for Translational CRISPR

  2026-07-30

  This article examines how high-yield in vitro RNA synthesis enables next-generation CRISPR applications in cancer biology, bridges mechanistic insight with strategic guidance, and positions the HyperScribe™ T7 High Yield RNA Synthesis Kit as a transformative tool for translational researchers.

• Tumor-Targeted PAD4 Inhibition Suppresses NETs and Metastasi

  2026-07-30

  This study introduces a meta-phenylboronic acid–modified PAD4 inhibitor (Compound 5i TFA) that selectively targets tumor cells to inhibit the PAD4–H3cit–NETs pathway, thereby suppressing tumor growth and metastasis in vivo. The findings highlight a new strategy for modulating the tumor immune microenvironment with high efficacy and minimized systemic toxicity.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Precision Δ

  2026-07-29

  Explore how the JC-1 Mitochondrial Membrane Potential Assay Kit enables precise mitochondrial membrane potential assays to unravel immunogenic cell death and drug effects. This article provides advanced, evidence-driven guidance for optimizing apoptosis and mitochondrial function analysis.

• Erlotinib (NSC 718781): Precision EGFR Inhibition in Oncolog

  2026-07-29

  Explore how Erlotinib, a potent EGFR tyrosine kinase inhibitor, empowers translational cancer research through advanced mechanistic insights and assay optimization. Uniquely, this article bridges SCUBE3 biology with practical protocol guidance, setting a new standard for experimental rigor.

• Dabigatran in Thromboembolic Disorders: Evidence and Researc

  2026-07-28

  Enriquez et al. present a comprehensive review of dabigatran, the first direct thrombin inhibitor among non-vitamin K oral anticoagulants, emphasizing its predictable pharmacokinetics, efficacy, and safety profile. The findings offer critical guidance for researchers and clinicians investigating anticoagulation strategies and model systems relevant to platelet and vascular function.

• Streamlining Bitespiramycin Production via Targeted Gene Del

  2026-07-28

  This study introduces a genetic strategy to simplify bitespiramycin biosynthesis by in-frame partial deletion of the 3-O-acyltransferase gene in Streptomyces spiramyceticus. The resulting strain produces predominantly 400-isovalerylspiramycin I, facilitating improved quality control and enabling more precise antimicrobial research applications.

452 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page